Nuvectis pharma, inc.NVCT.US Overview

US StockHealthcare

(No presentation for NVCT)

Overview AI Analysis AI Earnings Summary Financials Financial Forecast Stock Sentimental Institutions TradingView Chart

NVCT Overall Performance

NVCT AI Analysis & Strategy

NVCT Recent Performance

7.57%

Nuvectis pharma, inc.

0.81%

Avg of Sector

-1.14%

S&P500

NVCT PowerScanner

NVCT Key Information

NVCT Valuation Metrics

NVCT Earnings Table

NVCT Profile

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.